Total Pageviews

Senators Introduce Bill to Separate Trading Activities From Big Banks

Senator Elizabeth Warren on Thursday introduced an aggressive piece of legislation that intends to take the financial industry back to an era when there was a strict divide between traditional banking and speculative activities.

The bill, which is also sponsored by Senator John McCain, Republican of Arizona, and two other senators, is named the 21st Century Glass-Steagall Act. Its intention is to create a modern version of the seminal Glass-Steagall legislation from the 1930s, which placed firm limits on what regulated banks could do. It was fully repealed in 1999, laying the groundwork for the mergers that created some of the biggest banks of today. If passed, it could force many of those banks to let go of their trading operations.

Senator Warren’s bill is one of several that have aimed to add far more bite to the overhauls that have been put in place since the financial crisis. The bill serves as a jarring reminder to Wall Street of why it feared her election to the Senate last year.

“Over the past five years, we’ve made real progress,” said Senator Warren, Democrat of Massachusetts. But, she added, “The biggest banks continue to engage in dangerous high-risk practices that could once again put our economy at risk.”

Similarly stringent banking bills introduced in the last few years have struggled to gain sufficient votes in Congress, and this one may be no different. In addition, a move as radical as splitting up large banks is highly unlikely to gain the support of top regulators like the Federal Reserve or the Treasury Department.

“It seems mainly symbolic,” Phillip L. Swagel, a professor at the University of Maryland School of Public Policy, said. “This is a handle that people can grab to move the debate toward more regulation.”

Senator Warren seemed to acknowledge the battle ahead, but she said that having Senator McCain as an ally was an advantage. “He’s a fighter, and it’s going to take a fighter to get this Glass-Steagall bill through,” she said in a news conference.

Nostalgia for the original Glass-Steagall Act might help the new bill gain interest. Its supporters say the former law had several straightforward benefits, in contrast to the complex regulations that have been put in place since the crisis, like the Dodd-Frank Act of 2010. Glass-Steagall, which had 37 pages, was simple and so easy to put into practice, they say.

The act also kept banks that use federal deposit insurance out of potentially volatile Wall Street activities, like trading. As a result, problems at investment banks were less likely to infect regulated banks. Losses at the Wall Street operations of Citigroup and Bank of America weighed heavily on those banks during the 2008 crisis.

“For about 70 years, Glass-Steagall managed to keep the riskier, more damaging part of Wall Street away from what should be the boring, straightforward side of finance,” Barry L. Ritholtz, chief executive of FusionIQ, an asset management and research firm, said. “It was the height of stupidity repealing Glass-Steagall.”

During the era of Glass-Steagall, there were no systemic banking crises like the one that occurred in 2008. The restrictions the bill put on the financial sector did not seem to do much wider harm. According to analysis of government gross domestic product statistics, the American economy grew an average of 4 percent a year from 1933 until 1999, when Glass-Steagall was in effect. Even some who championed repealing the act, like the former Citigroup chairman Sanford I. Weill, have since called for the breakup of the bank behemoths.

Still, critics have a full arsenal of arguments to deploy against reintroducing it.

One is that Glass-Steagall would not have stopped the 2008 crisis. The act, for instance, would not have prohibited the growth of Lehman Brothers, which collapsed and spread panic through the financial system.

Another argument is that the American economy actually benefits from large banks that can make ordinary loans as well as trade securities and derivatives, the financial instruments that are used for hedging risks and speculation.

“On the whole, there are benefits to having diversified financial institutions,” said Mr. Swagel, who was an assistant secretary for economic policy under Treasury Secretary Henry M. Paulson Jr.

Others say there are much better tools to make the banks safer than a new Glass-Steagall, like requiring them to hold more capital.

“It is a very crude tool to be used to downsize the large banking organizations,” Charles M. Horn, a partner at the law firm Morrison & Foerster, said.

The new bill aims to update the old Glass-Steagall for innovations that have taken place since it was enacted. The new bill would force deposit-taking banks to cease most of their trading of derivatives. Today, banks keep most of their derivatives in entities that have deposit insurance, allowing them to benefit from an effective subsidy.

The bill would give banks five years to comply with its requirements.

The other two senators sponsoring the bill are Maria Cantwell, Democrat of Washington, and Angus King, independent of Maine.

On Thursday, Senator Warren said she was not convinced that banks needed to be on Wall Street as well as in traditional business to properly serve the economy.

“I’d like to see the data on that, because I haven’t,” she said.

The bill should not be seen as a cure-all, the senator cautioned.

“The bill by itself will not end ‘too-big-to-fail’ and implicit government subsidies, but it will make financial institutions safer and smaller and move us in the right direction,” she said.



16 Senators Seek Inquiry of A.T.M.-Style Pay Cards

Sixteen Democratic senators are asking regulators to examine the use of A.T.M.-style cards to pay hourly employees.

In a letter on Thursday, the senators urged Richard Cordray, the director of the Consumer Financial Protection Bureau, and Seth D. Harris, the acting secretary of the Labor Department, to “take swift action to protect American workers.”

Across the country, a growing number of companies are doing away with paper paychecks and, in some instances, direct deposit, to offer prepaid cards.

The problem, though, according to consumer lawyers and employees, is that in the vast majority of cases, using the cards can generate large fees â€" 50 cents for a balance inquiry and $2.25 for an out-of-network automated teller machine, for example. For part-time and low-wage workers, the fees, which can be difficult to escape, quickly devour much of the money deposited on the cards.

Worried about drawing unwanted scrutiny that might threaten their jobs, some employees say they are reluctant to request another option. Other employees say that while there is a choice, they are automatically enrolled in the payroll-card programs. Getting out, these employees say, can be difficult and confusing.

Card issuers and employers note that payroll cards are a valuable tool for low-wage workers. They also say the fees on the cards are usually lower than those charged by check-cashing services â€" often the only other option for people who do not have bank accounts. The card providers and employers also note that there are free ways for employees to gain access to their pay.

The Network Branded Prepaid Card Association, a trade group that represents the prepaid industry, said it urged its members to clearly outline any fees associated with the cards to ensure that employees understand every aspect of the card.

“We strive to ensure we set a high bar with our best practices for our members,” said Judith E. Rinearson, a lawyer with the trade group.

The surge in payroll cards and the problems associated with them was the subject of a front- page article in The New York Times last month.

In their letter, the lawmakers referred to the article in The Times, noting that it had been jarring to learn from the article that “some workers incur so many fees in the course of using their payroll cards that their net income ends up below the minimum wage.”

The senators, including Richard J. Durbin of Illinois, Charles E. Schumer of New York and Joe Manchin III of West Virginia, asked the regulators to examine whether workers understood the fees associated with the cards. The lawmakers also asked the Consumer Financial Protection Bureau to make a systematic study of the fees, according to the letter.

Senator Elizabeth Warren, a Democrat from Massachusetts, who helped create the new consumer protection agency, also signed the letter.

Mr. Manchin said, “Americans work hard every day and their pay must be protected from high fees, unfair choice and improper commissions. It is clear that prepaid payroll cards must be investigated further.”

The most vexing aspect of the cards, the lawmakers said, was that employees might be “coerced or inappropriately pressured into using them.” Employees, the letters says, “should have the right not to use such a card and to instead receive their pay via a paper check or direct deposit.”

To address the issue, the lawmakers asked the Consumer Financial Protection Bureau to clarify what laws govern the issuance of payroll cards.

“We believe it would go a long way toward protecting workers if the bureau would clearly and specifically state its view on what is and is not allowed” under the primary federal law that governs the electronic transfer of funds.

In their letter, the lawmakers noted that the “vast majority of employers make a good-faith effort to comply with the law in paying their employees.”



Valiant Leads Investment Round in Brazilian Pharmacy Benefits Firm

SÃO PAULO, Brazil â€" Valiant Capital Management, a San Francisco-based hedge fund started by Chris Hansen, and Aberdare Ventures have jointly acquired a 45 percent stake in a pharmacy benefits company, ePharma.

The deal was a signal that despite Brazil’s current economic woes and looming inflation, health care here remains an attractive industry for investors.

Even though growth has slowed and inflation is looming in Brazil, health care remains a strong sector. In February, CVS Caremark said it had acquired Drogaria Onofre, a Brazilian drug store chain, and last year UnitedHealth Group acquired Amil Participacoes, an insurer and hospital operator.

EPharma, founded in 1999, has sought to tap into the Brazilian equivalent of pharmacy benefit management firms in the United States. EPharma serves as an intermediary between health insurance companies, employers and pharmaceutical companies. Its customers include Motorola, Petrobras, Unilever and ArcelorMittal.

The value of the Valiant and Aberdare investment is an estimated 169 million reais ($74.6 million). EPharma’s chief executive, Luiz Carlos Silveira Monteiro, said the purchase price was about 13 times ePharma’s expected earnings before interest, taxes, depreciation and amortization. The investment was a combination of primary and secondary transactions.

A pharmacy company, Pague Menos, still holds 26.21 percent of total shares after the new investment. Until now it had been the controlling shareholder. Mr. Silveira Monteiro now holds 10 percent.

Valiant, which led the financing round, and Aberdare were drawn to ePharma because of the large network it had with Brazilian pharmacy companies, according to a person briefed on the negotiations. Several of them were ePharma shareholders in its early years. This person, who asked to be unnamed because the talks were confidential, said that this new investment was intended to make ePharma less beholden to specific pharmacies and thereby providing greater growth potential.

In Brazil, pharmacy benefit managers have about 2 million members according to Vitor Paschoal, an analyst with Itau BBA. But there are expectations that the sector will grow.

Late last year Brazil’s National Health Insurance Agency, the main regulatory body, started allowing private insurance companies to offer separately priced prescription drug plans and offered them financial incentives to do so. In Brazil, private health plans do not typically include prescription drugs.

“This was the first sign that they will give more incentives in the future,” Mr. Paschoal said. “They want to make it happen.”

A second promising sign for sector in Brazil was UnitedHealth Group’s purchase of Amil Participacoes. Mr. Paschoal says that, “United knows how to operate P.B.M.’s and they could bring the knowledge to Brazil.”

EPharma’s main competitors here are Orizon, Vidalink and Funcionalcard.



Valiant Leads Investment Round in Brazilian Pharmacy Benefits Firm

SÃO PAULO, Brazil â€" Valiant Capital Management, a San Francisco-based hedge fund started by Chris Hansen, and Aberdare Ventures have jointly acquired a 45 percent stake in a pharmacy benefits company, ePharma.

The deal was a signal that despite Brazil’s current economic woes and looming inflation, health care here remains an attractive industry for investors.

Even though growth has slowed and inflation is looming in Brazil, health care remains a strong sector. In February, CVS Caremark said it had acquired Drogaria Onofre, a Brazilian drug store chain, and last year UnitedHealth Group acquired Amil Participacoes, an insurer and hospital operator.

EPharma, founded in 1999, has sought to tap into the Brazilian equivalent of pharmacy benefit management firms in the United States. EPharma serves as an intermediary between health insurance companies, employers and pharmaceutical companies. Its customers include Motorola, Petrobras, Unilever and ArcelorMittal.

The value of the Valiant and Aberdare investment is an estimated 169 million reais ($74.6 million). EPharma’s chief executive, Luiz Carlos Silveira Monteiro, said the purchase price was about 13 times ePharma’s expected earnings before interest, taxes, depreciation and amortization. The investment was a combination of primary and secondary transactions.

A pharmacy company, Pague Menos, still holds 26.21 percent of total shares after the new investment. Until now it had been the controlling shareholder. Mr. Silveira Monteiro now holds 10 percent.

Valiant, which led the financing round, and Aberdare were drawn to ePharma because of the large network it had with Brazilian pharmacy companies, according to a person briefed on the negotiations. Several of them were ePharma shareholders in its early years. This person, who asked to be unnamed because the talks were confidential, said that this new investment was intended to make ePharma less beholden to specific pharmacies and thereby providing greater growth potential.

In Brazil, pharmacy benefit managers have about 2 million members according to Vitor Paschoal, an analyst with Itau BBA. But there are expectations that the sector will grow.

Late last year Brazil’s National Health Insurance Agency, the main regulatory body, started allowing private insurance companies to offer separately priced prescription drug plans and offered them financial incentives to do so. In Brazil, private health plans do not typically include prescription drugs.

“This was the first sign that they will give more incentives in the future,” Mr. Paschoal said. “They want to make it happen.”

A second promising sign for sector in Brazil was UnitedHealth Group’s purchase of Amil Participacoes. Mr. Paschoal says that, “United knows how to operate P.B.M.’s and they could bring the knowledge to Brazil.”

EPharma’s main competitors here are Orizon, Vidalink and Funcionalcard.



Biotech Companies Surge as Investors Flock to Them

When Onyx Pharmaceuticals, a cancer drug developer, turned down a $10 billion acquisition bid by Amgen last month and put itself up for sale, its share price soared more than 50 percent, touching off an investor frenzy in biotechnology.

Among the beneficiaries was Epizyme, a newly public Massachusetts company that some Wall Street analysts predict could also become a takeover target. Shares of Epizyme, which is working on drugs to treat types of leukemia and lymphoma, have risen 20 percent since July 1, and they have more than doubled since the company’s initial public offering on May 31.

Six other biotechnology companies completed I.P.O.’s in June, and five or so are lined up behind them â€" an incredible run considering the window for biotech offerings had been all but slammed shut since the 2008 financial crisis. The hot streak has been driven largely by the potential for deal-making in the industry, investors and analysts said.

The feared “patent cliff” for brand-name drugs has caused billion-dollar blockbusters like Pfizer’s cholesterol drug Lipitor and Bristol-Myers Squibb’s blood thinner Plavix to lose ground to generic competition, so the pharmaceutical industry has been hunting for innovation among small biotechnology companies, as both takeover targets and licensing partners. There were five acquisitions of venture capital-backed biotech companies in the second quarter alone, according to data from Thomson Reuters and the National Venture Capital Association.

“I think the big pharma companies are going to continue to look outside to find the next wave of innovative therapies,” said Dennis Purcell, senior managing partner of Aisling Capital, a life sciences venture capital firm based in New York. On June 17, an Aisling portfolio company in San Diego, Aragon Pharmaceuticals, which has a prostate cancer treatment in midstage human trials, was bought by Johnson & Johnson for $650 million up front, plus the potential for an additional $350 million in payments tied to research milestones.

Still, biotechnology is more prone to disappointments than perhaps any other industry â€" a risk that came to light not long before this recent run of I.P.O.’s. In May, shares of a former high flyer, Aveo Pharmaceuticals, fell nearly 50 percent when an advisory panel to the Food and Drug Administration urged the agency to reject the company’s kidney cancer drug because of questions about its efficacy.

That so many investors have been able to overlook such uncertainty and jump into a new class of companies with unproved science shows a new tolerance for risk on the public market, some experts say. The robust deal-making environment helps.

“People are hungry for growth,” said Erik Gordon, a professor specializing in life sciences entrepreneurship at the University of Michigan’s business school. “When you see something like Onyx telling Amgen” its offering price is too low, “you have to ask, what’s the downside? The downside is bad news, but if that doesn’t happen, the company you’ve invested in could be taken out at a huge gain.”

The 16 biotechnology companies that have gone public this year are up 48 percent on average from their offering prices, according to data provided by Nasdaq. As of Tuesday, four of the top 10 performing companies on the Nasdaq year-to-date were biotechs: Stemline Therapeutics, Bluebird Bio, Epizyme and Prosensa Holding.

“The fact that these companies can get out reloads the capacity of the venture funders” to turn to the public markets, said Samuel Isaly, managing partner of OrbiMed Advisors, which manages the Eaton Vance Worldwide Health Sciences Fund in addition to private equity and hedge funds. “We’re back to the good old days of before the financial crash.”

The biotechnology I.P.O. market is so frothy, in fact, that some companies are not waiting to take advantage of it. Hans Schikan, the chief executive of the Dutch biotech company Prosensa, said he and his management team originally planned their I.P.O. for a week or so after the Fourth of July holiday, but when they saw the positive investor response to Epizyme and others, they rushed out on June 28 instead. “When the window’s open, you’d better use it,” Mr. Schikan said. Prosensa’s shares opened $7 above its $13 offering price and are up 102 percent so far.

One gateway for acquisitions in the biotech sector is research partnerships, and those are increasing as well.

Epizyme did not start human testing of its lead drug until late last year, but it attracted plenty of interest from big pharmaceutical companies long before that. The company formed research partnerships with GlaxoSmithKline, Celgene and Eisai, which together were worth $125 million in nonequity financing.

Simos Simeonidis, an analyst at Cowen & Company, predicts that if one of Epizyme’s two leading cancer drugs shows even a hint of success in clinical trials, “a lot of big pharmas or big biotechs are going to want to own the platform. The possibility of an acquisition in my mind would be very high,” he said.

Several other members of this year’s biotech I.P.O. class have rich partnerships. Bluebird Bio of Massachusetts signed a three-year oncology research deal with Celgene in March, which included a $75 million upfront payment. Bluebird’s I.P.O. was on June 19, and its stock has climbed 78 percent.

PTC Therapeutics, a New Jersey company that went public the next day and raised $114 million, has a $30 million deal with Roche to study treatments for spinal muscular atrophy, and an oncology partnership with AstraZeneca that included an undisclosed upfront payment. Both deals included the potential for milestone bonuses. Its shares have risen 9 percent.

Robert J. Gould, the chief executive of Epizyme, said he was well aware that research partnerships often blossomed into full-blown buyout offers. But “we have no intention of positioning ourselves to be acquired,” he said. Bluebird and PTC, which are both still in post-offering quiet periods, declined to comment.

Venture capitalists in life sciences predict that both the pace and the value of licensing deals will accelerate. “Pharma certainly is evaluating every single asset of every single company that’s out there and acting on it,” said Noubar Afeyan, managing partner and chief executive of Flagship Ventures, an investor in Agios Pharmaceuticals of Massachusetts, which announced its intention on June 10 to raise $86 million in an I.P.O. Agios has a $150 million cancer drug development deal with Celgene.

It is not just cancer treatment that is generating excitement among investors. Prosensa is developing drugs to treat Duchenne muscular dystrophy and other muscle disorders. PTC has its own treatment for muscular dystrophy and is also developing drugs to fight cystic fibrosis and infectious disease. The one unifying theme in all the companies that have generated excitement on Wall Street is the rise of personalized medicine, said Christoph Westphal, a longtime biotechnology entrepreneur and a founder and partner of the Longwood Fund. “Many companies that have done well recently have a specific molecular-medicine approach to a serious disorder that has no other therapies,” he said.

Prosensa’s two lead drugs for muscular dystrophy, for example, are being tested in small groups of patients whose disease is caused by specific genetic mutations, which can be detected with diagnostic devices that the company is using alongside the drugs.

Another factor working in the biotechnology industry’s favor is that regulators have become much more supportive in recent years of drugs that address high unmet medical needs. In July 2012, the Food and Drug Administration Safety and Innovation Act established the “breakthrough therapy” designation, which gave the agency the authority to speed its review of drugs to treat life-threatening ailments.

“The regulators, notably the F.D.A., have been particularly willing to come up with new strategies to enable the rapid development of drugs for which there is a dramatic effect in a defined patient population,” said Robert Tepper, a partner at Third Rock Ventures, which is an investor in both Bluebird and Agios. “If you can stratify the patient population you want to treat through genetic analysis, for example, you can move quite quickly through early-stage trials.”



At Sun Valley, Watching to See if the Chatter Is More Than Idle Talk

SUN VALLEY, Idaho â€" At the Allen & Company media and technology conference here, the name of the game is talk: Mainly, who’s talking with whom?

Stocked with moguls galore, the gathering is best-known for the deals that have emerged from hush-hush meetings that take place by this resort’s duck pond or in conference rooms at the Sun Valley Inn. Chief among those enshrined in conference lore was the merger of Disney and Capital Cities.

But a number of attendees played down the importance of deals hatched immediately at the conference. (That said, John C. Malone, who has reiterated here the need for consolidation within the cable industry, hustled to at least one meeting on Thursday morning.) Instead, coming to the Allen & Company conference largely allows moguls to see peers and discuss the state of their industries, as well as meet with potential new business partners.

With that in mind, here are a few intriguing conversation partners that DealBook has observed so far:

  • Peter Chernin of the Chernin Group and Jonathan Nelson of Providence Equity Partners, the media-focused private equity firm, midday on Wednesday. The two know each other well, with Providence having served as a financial backer to Mr. Chernin. Among their potential discussion topics: Chernin’s bid for Hulu, the online video service. The two are keeping mum about the current state of the sales process: all Mr. Chernin would say on Wednesday night was, “Go ask them,” referring to the media companies that own ulu.
  • Jack Dorsey, the co-founder of Twitter and the founder of the payments service Square, and Brian Grazer, the film and television producer. The two spent a bit of Wednesday together, even venturing off to skeet-shooting at the resort.
  • Jeffrey Katzenberg of Dreamworks Animation and Salar Kamangar, the head of YouTube, in a relatively quiet corner of the Sun Valley Lodge on Wednesday night.
  • Chase Carey, the chief operating officer of 21st Century Fox, and Haim Saban, the media investor, in the Lodge on Wednesday night. It was a conversation that at times drew in a few fellow media players, including Robert Iger, the chief executive of Disney.


In Battle Over Dell’s Fate, Don’t Underestimate Carl Icahn

Negotiation gurus say that if you think your opponent is foolish or stupid, it may well be you who is out-negotiated. I generally shrug off this type of pop business advice, but when we are talking about Carl C. Icahn, the investor whom I have likened to a Wile E. Coyote, it may be a wise adage.

I raise this after reading Mr. Icahn’s latest announcement to other shareholders of Dell Inc. urging them to start preparing appraisal rights for their shares.

At first blush, the announcement can be charitably described as a Hail Mary pass.

Appraisal rights have gotten a lot of attention in the Dell matter, but as I wrote last week in a post about the endgame for Dell, they are probably not a good option.

That’s because of the way appraisal works and the risks involved. Appraisal is a judicial proceeding in which the court will determine the fair value of the shares seeking appraisal. The idea is to give dissenting shareholders another, potentially more lucrative option than the $13.65-a share that Michael S. Dell and the investment firm Silver Lake are offering.

In Delaware, where Dell is incorporated, appraisal is a process that can take years as the court decides what is the fair value of the shares. It is essentially a battle of the experts. Each side puts financial experts on the stand to testify as to the fair value of Dell shares at the time of the merger. The court then determines the value that the dissenting shareholders get. But most important, the Delaware court can award more or less than the $13.65 being offered to Dell shareholders.

In many Delaware appraisal proceedings, the judge just splits the decision, awarding a value that falls between the experts’ recommendations and giving the shareholders a decent return for exercising their rights.

But the possibility of receiving less would probably be a bigger issue in Dell’s case than in other appraisal proceedings.

The judge in the shareholder litigation over the Dell buyout, who is also likely to hear the appraisal proceedings, Chancellor Leo E. Strine Jr., has already praised the Dell sale process. At a June hearing, he said, “I do not see any plausible, conceivable basis in which to conclude that it is a colorable possibility that you could deem the choices made by this board to be unreasonable with all the different safeguards.” And while appraisal looks at the value of the shares, and not the sale process, it is possible the process used here will affect the judge’s determination. It all means that there is a chance that the court will have an built-in bias against a significantly higher award than the amount being offered right now.

Even beyond that, fair value for appraisal is assessed at the time of the merger, not the time the deal was cut. And since the time this buyout was announced in February, Dell’s business appears to have deteriorated. As a result,Silver Lake and Mr. Dell can also argue that they are actually paying above fair value right now.

So in an appraisal proceeding, Mr. Icahn faces the real possibility of receiving less than $13.65 a share.

And there is another hurdle to appraisal proceedings in the Dell case. Mr. Icahn would not receive his money until the appraisal proceeding was over. The would mean that Mr. Icahn’s money would be tying up about $2 billion in capital for two or more years.

So what kind of return would Mr. Icahn get for tying up billions of dollars?

In a presentation to Dell, Mr. Icahn and his fellow dissident investor, Southeastern Asset Management, stated that the fair value of shares could be about $23 a share. Shareholders are also entitled to interest in any award in an appraisal rights proceeding. The interest rate is the federal discount rate plus 5 percent from the time the merger occurs until the award is paid (5.75 percent in total right now).

If the litigation takes three years, the best Mr. Icahn could make about a 25 to 30 percent annual return. But that is the best-case scenario. If you adjust these figures for the risk of losing, you may be looking at negative returns. This is particularly true when you take into account that Mr. Icahn could have been earning returns with this money.

Mr. Icahn, who is worth about $20 billion, did not become a billionaire by making bad investments. So unless there is a quick settlement, appraisal is probably a bad investment, and no investor intentionally makes bad investments.

In this light, Mr. Icahn’s announcement that he is preparing appraisal rights can be explained three ways:

1. He firmly believes he will win in an appraisal proceeding and thinks that the risk/return is appropriate.

2. He is hoping that enough people seek appraisal to get a quick settlement.

3. He has another strategy in mind, and this announcement is only one part of it.

The first option doesn’t seem likely unless Mr. Icahn is using different numbers.

As for the second possibility, Silver Lake and Mr. Dell are likely to call Mr. Icahn’s bluff and wait out the 60-day period after the merger â€" the period during which Dell shareholders are able to change their minds about whether to seek appraisal. Then, Mr. Dell and Silver Lake will negotiate with whomever is left. Why would Mr. Dell and Silverlake negotiate before the end of the 60 days? They might as well wait. Mr. Icahn talks about “getting lucky” by exercising your appraisal rights, but you may have a better chance of victory at the slots in Las Vegas.

In addition, Mr. Icahn stated in his announcement that if enough Dell shareholders dissent, the lenders on the deal might try to back out by claiming that the material adverse change clause in their lending agreement was triggered. This clause generally provides an out for the lenders if something material and adverse happens to Dell. But a MAC clause is difficult to invoke and must be unexpected and unanticipated. Appraisal rights are a wholly expected outcome of a merger, and so it is hard to see how their exercise could trigger the MAC clause.

So while Mr. Icahn mentioned the possibility, it is unlikely to work.

This leaves Option 3, and here we have that negotiating principle I wrote of at the beginning.

Assuming that Mr. Icahn is doing the same math, he knows this is a gambit. In this case though, perhaps he is trying to throw everything up against the wall. But, perhaps, there is an alternate explanation. To exercise appraisal you have to vote no for the deal, and notify Dell before the vote occurs. By preparing appraisal rights, Mr. Icahn may be making a Hail Mary pass, but one aimed at signaling “no” votes before the actual shareholder vote. Perhaps he is merely trying to show that he has a bigger block of “no” votes than Mr. Dell and Silver Lake think. It’s a small bargaining chip, but at this point everything counts.

Still this is pure speculation, and Mr. Icahn’s options don’t look particularly appealing, no matter the explanation for his latest action. Nonetheless, it never pays to underestimate Carl Icahn.



Big Paymout by Moelis May Whet the Appetite for More

Moelis & Company’s $35 million payout to its mainly staff owners shows the partnership model in investment banking can deliver. The maiden distribution is part balance-sheet tending, part carrot to stop staff jumping ship. The snag is that Moelis’ liquidity-deprived partners will expect a repeat.

The quasi-dividend is worth less than $300,000 per partner. But it provides an incentive for executives to stick with their firm. Previously, their only remuneration in addition to salary and bonus was in small tax rebates linked to their equity share. Rival bankers at listed boutiques like Evercore or Greenhill can convert the shares they earn into hard cash after a typical three-year vesting period.

Moelis bankers will now expect such payments to come every year â€" and to grow in size. Indeed, the payout’s timing â€" almost exactly halfway between year-end bonus payments â€" signals this is no one-off. The firm has kept some cash in reserve, according to a person familiar with the situation. So there should be enough for a further payment in 2014 and possibly beyond.

But is it really sustainable? Moelis is a fast-growing firm and expansion hasn’t come cheap. It takes time for new hires to turn into revenue. Headcount has surged from 20 to 600 in the six years of its existence. League tables tell a conflicting story: Moelis is ranked 10th for announced U.S. M&A this year, but is outside the top 25 in Europe, the Middle East and Africa, Thomson Reuters data show. Moelis’ British business made a loss in 2011, its most recent accounts show.

The summer dividend payments should help bind the firm together however well any one geography is doing. A global revenue sharing agreement already rewards London-based bankers for advising on pitchbooks and deals from Baltimore to Beijing.

If the dividend isn’t sustained and increased, retaining staff will get harder. A handful of senior bankers have left in the last year. Partnerships will always be under pressure to dissolve and give staff an exit. Even Goldman Sachs, which Moelis is trying to ape, succumbed to an initial public offering in the end.

Dominic Elliott is a columnist at Reuters Breakingviews. For more independent commentary and analysis, visit breakingviews.com.



Jurors to Hear About the Fabulous Fab

It’s hard to live down a nickname.

Fabrice Tourre, the former Goldman Sachs trader whose civil trial is scheduled to begin Monday, has tentatively lost his bid to exclude from evidence an e-mail that references the nickname “Fabulous Fab,” given to him, he says, by a friend.

Judge Katherine Forrest of Federal District Court in Manhattan filed a preliminary decision on the e-mail on Wednesday, indicating that she overruled his request to keep it away from jurors’ eyes. Mr. Tourre is fighting accusations brought by the Securities and Exchange Commission that he was part of a conspiracy to mislead investors when selling a mortgage security in 2007 that ultimately failed.

Since the e-mail first came light in April 2010, the nickname has stuck, and Mr. Tourre is widely known on Wall Street as the Fabulous Fab.

The e-mail was one of many Mr. Tourre wrote to his girlfriend, in which he joked about the downfall of the mortgage market. “The whole building is about to collapse anytime now,” he said, adding that he was the “only potential survivor” of these “complex, highly leveraged, exotic trades he created.” He also noted that a friend “kindly” labeled him the “fabulous Fab,” even though “there is nothing fabulous about me.”

Matthew T. Martens, chief litigation counsel in the S.E.C.’s enforcement department, said in court on Tuesday that he wanted to refer to the e-mails in his opening statement. He said the e-mails “go directly to his state of mind”.

John “Sean” Coffey, a lawyer for Mr. Tourre, argued the e-mails were private and not related to the case.

The trial is expected to last about three weeks and will be heard by nine jurors.

Goldman was charged alongside Mr. Tourre but opted to settle, paying a record $550 million without admitting or denying guilt.



Upheaval in the E-Book World

There have been some big shifts in e-books lately.

First, a judge this week found that Apple was guilty of price-fixing e-books â€" colluding with other e-book vendors to keep prices high. Apple says it will appeal the decision.

Second, Barnes & Noble’s chief executive, William Lynch, has resigned. He was appointed in March 2010 to lead the bookseller into the high-tech age (he had been an executive at Palm and Home Shopping Network). But sales haven’t been going well with Barnes & Noble, electronically or otherwise.

I’ve had my clashes with Mr. Lynch. Twice, I’ve publicly called out the company for cheating in the way it advertised its Nook e-readers. Once, it understated the Nook’s weight by an ounce. Another time, it advertised a Nook to have a high-definition screen when it didn’t.

“Look, Barnes. Listen, Noble,” I wrote. “You have a perfectly good product. You don’t have to stretch the truth to sell it.”

Mr. Lynch called me up, deeply upset, to ask if I had some kind of ax to grind with Barnes & Noble (I didn’t, and don’t). But in both cases, he did order the advertising changed to correct the misleading specs.

But his departure, I suspect, has to do with the failure of the Nook over all. According to the research firm IDC, Barnes & Noble’s tablet market share wasn’t even in the top five for the first three months of this year.

Last week, Barnes & Noble said that it would stop making color Nook tablets. That’s it: Amazon won that battle, and has no more competition.

(Barnes & Noble says that the color tablets will be “co-branded with yet-to-be-announced third-party manufacturers of consumer electronics products,” whatever that means. Barnes & Noble will still design and sell the black-and-white tablets, like the Nook SimpleTouch and Glowlight.)

It’s really too bad. The color Nooks were easily competitive with Amazon’s Kindle Fire â€" better in many ways. The color Nooks could run any Android app, not just a handpicked special selection. They have memory-card slots so you can expand the storage.

In fact, CNET argues that there’s never been a better time to buy a color Nook, since the company has slashed the prices. At the moment, they cost far less than Amazon’s equivalent Kindle: $130 for the 7-inch model (Amazon’s is $200), $150 for the 9-incher (Amazon’s is $270).

The problem, of course, is the copy protection. Idiotically, each tech giant in the e-book game (Apple, Amazon, Barnes & Noble) developed a different, incompatible form of copy protection for its books. Once Barnes & Noble drops out of the game completely, any e-books you bought for your Nook will probably become unreadable. Betamaxed, you might say.

(Yes, there are Nook apps for Mac and Windows, but Barnes & Noble abandoned them some time ago. There’s also a way to read these books on a Web page, but it doesn’t work for many e-book titles. The company still has a Windows 8 app that can read its books.)

So the bottom line is all bad news. People who bought e-books from Barnes & Noble may wind up with libraries they can’t read. Amazon no longer has a competitor to keep it on its toes (and its prices low). The future of Barnes & Noble’s e-book business now looks murky, which means that even more customers will stay away, creating a vicious cycle of declining sales.

In the end, it may be that all we can salvage from this smoking mess is a lesson or two â€" although what they might be escapes me at the moment.



Upheaval in the E-Book World

There have been some big shifts in e-books lately.

First, a judge this week found that Apple was guilty of price-fixing e-books â€" colluding with other e-book vendors to keep prices high. Apple says it will appeal the decision.

Second, Barnes & Noble’s chief executive, William Lynch, has resigned. He was appointed in March 2010 to lead the bookseller into the high-tech age (he had been an executive at Palm and Home Shopping Network). But sales haven’t been going well with Barnes & Noble, electronically or otherwise.

I’ve had my clashes with Mr. Lynch. Twice, I’ve publicly called out the company for cheating in the way it advertised its Nook e-readers. Once, it understated the Nook’s weight by an ounce. Another time, it advertised a Nook to have a high-definition screen when it didn’t.

“Look, Barnes. Listen, Noble,” I wrote. “You have a perfectly good product. You don’t have to stretch the truth to sell it.”

Mr. Lynch called me up, deeply upset, to ask if I had some kind of ax to grind with Barnes & Noble (I didn’t, and don’t). But in both cases, he did order the advertising changed to correct the misleading specs.

But his departure, I suspect, has to do with the failure of the Nook over all. According to the research firm IDC, Barnes & Noble’s tablet market share wasn’t even in the top five for the first three months of this year.

Last week, Barnes & Noble said that it would stop making color Nook tablets. That’s it: Amazon won that battle, and has no more competition.

(Barnes & Noble says that the color tablets will be “co-branded with yet-to-be-announced third-party manufacturers of consumer electronics products,” whatever that means. Barnes & Noble will still design and sell the black-and-white tablets, like the Nook SimpleTouch and Glowlight.)

It’s really too bad. The color Nooks were easily competitive with Amazon’s Kindle Fire â€" better in many ways. The color Nooks could run any Android app, not just a handpicked special selection. They have memory-card slots so you can expand the storage.

In fact, CNET argues that there’s never been a better time to buy a color Nook, since the company has slashed the prices. At the moment, they cost far less than Amazon’s equivalent Kindle: $130 for the 7-inch model (Amazon’s is $200), $150 for the 9-incher (Amazon’s is $270).

The problem, of course, is the copy protection. Idiotically, each tech giant in the e-book game (Apple, Amazon, Barnes & Noble) developed a different, incompatible form of copy protection for its books. Once Barnes & Noble drops out of the game completely, any e-books you bought for your Nook will probably become unreadable. Betamaxed, you might say.

(Yes, there are Nook apps for Mac and Windows, but Barnes & Noble abandoned them some time ago. There’s also a way to read these books on a Web page, but it doesn’t work for many e-book titles. The company still has a Windows 8 app that can read its books.)

So the bottom line is all bad news. People who bought e-books from Barnes & Noble may wind up with libraries they can’t read. Amazon no longer has a competitor to keep it on its toes (and its prices low). The future of Barnes & Noble’s e-book business now looks murky, which means that even more customers will stay away, creating a vicious cycle of declining sales.

In the end, it may be that all we can salvage from this smoking mess is a lesson or two â€" although what they might be escapes me at the moment.



Bumi Chairman Agrees to Buy Out Bakrie Family

LONDON - In the latest twist in a long-running dispute about control of the coal producer Bumi, its chairman, Samin Tan, agreed on Thursday to buy the stake owned by the Bakrie family of Indonesia, a step opposed by the financier Nathaniel Rothschild.

Mr. Tan agreed to pay $223 million for the Bakrie family’s 23.8 percent stake in Bumi, which is based in Indonesia but listed on the London Stock Exchange. The purchase would make Mr. Tan the biggest shareholder in Bumi with a 47.6 percent holding. Mr. Rothschild owns about 15 percent of the company.

Mr. Rothschild, the former co-chairman of the hedge fund Atticus Capital and member of the British Rothschild banking dynasty, co-founded Bumi with the Bakrie family, one of Indonesia’s wealthiest, in a $3 billion deal in 2011. The idea was to create a giant in the coal and iron ore market by adding to existing assets in Indonesia, Mauritania and Yemen through acquisitions.

But the global economic slowdown hurt Bumi’s business and a boardroom fight over control and strategy followed. Bumi’s share price slumped. Mr. Rothschild, who fell out with the Bakries over some suspicious transactions and an investigation into suspected accounting irregularities, has since said it was a mistake to team up with the Bakrie family for the venture.

After a failed attempt to regain control of Bumi in February, Mr. Rothschild started to work on unwinding his links with the Bakries. If it goes ahead, Mr. Tan’s purchase announced on Thursday would end the Bakrie family’s direct link with Bumi, but Mr. Rothschild criticized the deal for being unfair to existing shareholders, who he contends should have the right to buy the stake instead.

“Moreover, the primary source of Bumi’s difficulties over the past three years has been the concentrated control by the Bakrie Concert Party, which included Samin Tan,” Mr. Rothschild said in a statement. “This deal does not change that.”

As part of the deal agreed with Mr. Tan, the Bakries would also buy back a minority stake in the coal company Bumi Resources from Bumi for more than $500 million. Mr. Rothschild argued that this would deprive minority investors of any upside just as the market for coal improves.

The fight for control at Bumi highlighted the issue of the protection of minority shareholders.

On Thursday, the Association of British Insurers, whose members have more than 1.8 trillion pounds ($2.7 trillion) of funds under management as institutional investors, called for stricter rules for companies with majority shareholders that apply for a listing on the London Stock Exchange.

Majority shareholders should be held responsible for the content of the share sale prospectus and be clearer about what relationship they expect to have with the company and minority shareholders, the group said in a report published on its Web site.

The report comes after some investors warned that share listings of companies where one investor keeps a large stake, including Bumi and the Eurasian Natural Resources Corporation, which is controlled by billionaire businessmen from Kazakhstan, could harm the reputation of London as a financial center.



An Accord on Regulating Overseas Trading

Regulators in Washington have agreed in principle on a plan to rein in risky trading by banks overseas, after a messy split in the Commodity Futures Trading Commission, DealBook’s Ben Protess reports. The potential deal, subject to final approval by the agency, would be reached with hours to spare before a deadline on Friday, according to people briefed on the matter.

“The dispute traced largely to the agency’s Democratic chairman, Gary Gensler, and Mark Wetjen, a Democratic commissioner with an independent streak,” Mr. Protess writes. “But in recent days, they showed signs of progress. Mr. Gensler and Mr. Wetjen have been meeting in person throughout the week, the people briefed on the matter said, and had struck a preliminary deal by Wednesday. While both are likely to claim victory, the deal does not come without sacrifice for each side.”

“The contours of the plan, the people briefed on the matter said, suggest that firms like Goldman Sachs International and Citigroup’s London branch will face a wave of new scrutiny, a sticking point for Mr. Gensler. In a move likely to appease Mr. Wetjen, Mr. Gensler is expected to phase in the cross-border oversight. And in a concession to Wall Street and foreign finance ministers, the plan would defer to European regulators if they ultimately agree to scrutinize banks in a way that is similar to the monitoring by the trading commission,” Mr. Protess writes. “The people briefed on the matter, who insisted on anonymity to discuss private negotiations, cautioned that the deal was not final.”

S.E.C. LIFTS AN ADVERTISING BAN  | 
“Federal regulators on Wednesday lifted an 80-year-old ban on advertising by hedge funds, buyout firms and start-up companies seeking capital, a move that will fundamentally change the way that many issuers raise money in the private marketplace,” DealBook’s Peter Lattman reports. “The Securities and Exchange Commission voted to approve a rule that Congress included in last year’s Jumpstart Our Business Start-Ups Act, a law meant to help bolster small businesses and create jobs after the financial crisis.”

“The move allows start-ups and small businesses to use advertising to raise money through private offerings. Hedge funds and buyout firms, whose investment vehicles fall under regulations for private offerings, will also be able to promote their products to the general public, though restrictions remain on who can invest in them. Some regulators, lawmakers and consumer protection groups faulted the S.E.C.’s decision. Luis A. Aguilar, the lone dissenter among the S.E.C.’s five commissioners, called the adoption of the rule reckless. He said it was being approved without appropriate investor safeguards and worried that it would lead to abuse.”

SENATORS QUESTION CHINESE TAKEOVER OF SMITHFIELD  |  Members of the Senate Agriculture Committee raised questions on Wednesday about the economic and national security implications of the takeover of Smithfield Foods, the nation’s largest pork producer, by Shuanghui International, a Chinese company. While the chief executive of Smithfield, C. Larry Pope, said the $4.7 billion acquisition would have “no impact on the U.S. food supply and, therefore, no impact on food security,” several senators said they feared that promises by Shuanghui would not be honored over the long term, Edward Wyatt reports in DealBook. That could result, they said, in China eventually exporting pork to the United States that did not meet American safety standards or taking away sales by American companies in other overseas markets, like Japan.

ON THE AGENDA  | 
Texas Industries reports earnings in the morning. Infosys reports earnings after the market closes. Barry Silbert, chief executive of SecondMarket, is on CNBC at 8:10 a.m. Marc Andreessen of Andreessen Horowitz, is on Bloomberg TV at 3 p.m.

A CONSPICUOUS ABSENCE IN SUN VALLEY  |  Many prominent deal makers have descended on the Allen & Company media and technology conference in Sun Valley, Idaho. But one of the most-mentioned individuals is absent: Larry Page, the chief executive of Google. “The search giant is well represented by a number of senior executives, to be sure. Eric Schmidt, the company’s executive chairman, is here. So are Nikesh Arora, its chief business officer, and Salar Kamangar, the chief executive of its YouTube division,” DealBook’s Michael J. de la Merced writes. “But it’s Mr. Page, whom several attendees said they had been hoping to hear speak on Wednesday morning, whose name cropped up an awful lot. The chief executive has disclosed that he suffers from a chronic illness that affects his vocal cords and breathing.”

Still, other chief executives were milling about. Leslie Moonves of CBS said that he was not looking to buy TV stations, but “If they fit, we would” take a look. Jeffrey L. Bewkes, chief of Time Warner, said he thought Aereo, a streaming TV service, is “irrelevant” and that the best buyer of Hulu is Hasbro.

Mergers & Acquisitions »

Sprint Completes Its Deal With SoftBank  |  Sprint said its deal to sell a controlling stake to SoftBank of Japan closed on Wednesday, after a drawn-out bidding process. Sprint is shedding “Nextel” from its corporate name, AllThingsD notes. ALLTHINGSD

Inside Lampert’s Sears  |  Many of the troubles at Sears can be linked to an organizational model that Edward S. Lampert, the chairman, implemented five years ago, Mina Kimes writes in Bloomberg Businessweek. BLOOMBERG BUSINESSWEEK

Noble Group Said to Weigh Bid for Australian Miner  |  The Noble Group is considering a bid for Western Desert Resources, “in what would be one of the biggest deals for an Australian iron-ore miner since prices weakened last year, according to people familiar with the matter,” The Wall Street Journal reports. WALL STREET JOURNAL

Icahn’s Latest Gamble at Dell: Appraisal Rights  |  Carl C. Icahn’s call for shareholders to exercise their appraisal rights is in some ways a surprising shift, since he has pushed them to reject the takeover bid. But it may be a last-ditch effort to seek a higher payout even if the deal goes through. DealBook »

Tribune to Split Newspapers and TV  |  The Tribune Company announced on Wednesday that it would spin off its newspapers and broadcasting properties into separate companies. DealBook »

Why Italy Could Be Fertile Ground for Deal Makers  |  Italy’s shaky state should not be an insurmountable obstacle to foreign investment, Quentin Webb of Reuters Breakingviews writes. Foreign deal makers just need to find ways to coax Italy’s aging entrepreneur-owners to the table. REUTERS BREAKINGVIEWS

INVESTMENT BANKING »

At Deutsche Bank, Loans That Are Less Than Transparent  |  Deutsche Bank “made billions of dollars of loans to banks worldwide since 2008 and accounted for them in a way that obscured their continuing risk to investors,” Bloomberg News reports. BLOOMBERG NEWS

An Improvement in How Banks Are Perceived by Consumers  |  Perceptions of Goldman Sachs, Bank of America, JPMorgan Chase and Morgan Stanley have improved in the first half of year compared with a year earlier, according to the YouGov BrandIndex. YOUGOV

Evercore to Start a Private Capital Advisory Business  |  Evercore Partners, an investment banking advisory firm, said on Wednesday that it was starting a private capital advisory business and had hired two UBS bankers to lead it. DealBook »

Barclays Wins Dismissal of Lawsuit Over Sale of Securities  |  A judge dismissed a lawsuit from the National Credit Union Administration, which regulates credit unions, over the sale of more than $555 million of mortgage-backed securities to two credit unions, Reuters reports. REUTERS

PRIVATE EQUITY »

A Bleak Outlook for Private Equity in India  |  Nikhil Raghavan, a principal at Bain Capital in Mumbai, predicted that private equity investments in India would probably fall this year because of a lack of opportunities, The Wall Street Journal writes. WALL STREET JOURNAL

HEDGE FUNDS »

Hedge Fund Glory Days May Be Over  |  “After a decade as rock stars, hedge fund managers seem to be fading just as quickly as musicians do,” Sheelah Kolhatkar writes in the Bloomberg Businessweek cover story. BLOOMBERG BUSINESSWEEK

Adventures Abroad Could Hurt U.S. Companies  |  It is astounding how little risk the markets are pricing into public companies that have poured shareholder money into emerging markets over the last several years through acquisitions and start-up projects, writes Carson C. Block, the director of research for the investment firm Muddy Waters. DealBook »

LightSquared to Go to Trial With Lenders  | 
REUTERS

I.P.O./OFFERINGS »

Royal Mail Employees to Get Free Shares in I.P.O.Royal Mail Employees to Get Free Shares in I.P.O.  |  The British government’s plans to sell a majority stake in Royal Mail would be the biggest privatization in the country since the railroads 20 years ago. DealBook »

VENTURE CAPITAL »

With a Silicon Valley Fortune, a Hunt for Political Office  |  Sean Eldridge, the husband of the Facebook co-founder Chris Hughes, has relocated in a quest for a congressional seat in New York, The New York Times writes. “But his ambitions have puzzled some residents among the farmers, mill workers and small-business owners who populate this district, which rises through the Catskills and rolls north through cornfields and apple orchards to the Vermont border.” NEW YORK TIMES

LEGAL/REGULATORY »

At Fed, Diverging Debate on When to End Stimulus  |  The New York Times reports: “The Federal Reserve chairman, Ben S. Bernanke, said on Wednesday that the Fed was likely to extend the centerpiece of its campaign to bolster the economy â€" keeping short-term interest rates close to zero â€" even as it prepares to wind down another key stimulus program that faces mounting internal opposition.” NEW YORK TIMES

Fed’s Easing of Stimulus Could Hamper European Recovery  |  “Recent fears that the Federal Reserve could begin withdrawing its economic stimulus have prompted interest rates to rise around the world, putting business loans further out of reach for companies in Spain, Italy and France,” The New York Times writes. NEW YORK TIMES

Massachusetts Regulator Opens Inquiry Into Products Sold to Older Investors  |  The top financial regulator in Massachusetts has asked 15 brokerage firms, including Merrill Lynch and LPL Financial, about the way they have marketed “high-risk, esoteric products” to older investors. DealBook »

The Consequences of Apple’s Loss on E-Books  |  A federal judge on Wednesday ruled that Apple had violated antitrust law in conspiring with publishers to raise prices of e-books. “Although it appears unlikely that the ruling will have an immediate effect on the book-buying public, it could affect how Apple cuts deals with media companies that provide the music, books and movies that help make its iPhones and iPads compelling,” The New York Times reports. NEW YORK TIMES

What Is Bank Capital, Anyway?  |  Though capital is a centerpiece of Wall Street regulation, it resists a simple definition.
DealBook »

China’s Growth Woes Could Force Government Response  |  The Chinese government’s response to weak economic data will be a test of the nation’s new leadership, Bill Bishop writes in the China Insider column. DealBook »



An Accord on Regulating Overseas Trading

Regulators in Washington have agreed in principle on a plan to rein in risky trading by banks overseas, after a messy split in the Commodity Futures Trading Commission, DealBook’s Ben Protess reports. The potential deal, subject to final approval by the agency, would be reached with hours to spare before a deadline on Friday, according to people briefed on the matter.

“The dispute traced largely to the agency’s Democratic chairman, Gary Gensler, and Mark Wetjen, a Democratic commissioner with an independent streak,” Mr. Protess writes. “But in recent days, they showed signs of progress. Mr. Gensler and Mr. Wetjen have been meeting in person throughout the week, the people briefed on the matter said, and had struck a preliminary deal by Wednesday. While both are likely to claim victory, the deal does not come without sacrifice for each side.”

“The contours of the plan, the people briefed on the matter said, suggest that firms like Goldman Sachs International and Citigroup’s London branch will face a wave of new scrutiny, a sticking point for Mr. Gensler. In a move likely to appease Mr. Wetjen, Mr. Gensler is expected to phase in the cross-border oversight. And in a concession to Wall Street and foreign finance ministers, the plan would defer to European regulators if they ultimately agree to scrutinize banks in a way that is similar to the monitoring by the trading commission,” Mr. Protess writes. “The people briefed on the matter, who insisted on anonymity to discuss private negotiations, cautioned that the deal was not final.”

S.E.C. LIFTS AN ADVERTISING BAN  | 
“Federal regulators on Wednesday lifted an 80-year-old ban on advertising by hedge funds, buyout firms and start-up companies seeking capital, a move that will fundamentally change the way that many issuers raise money in the private marketplace,” DealBook’s Peter Lattman reports. “The Securities and Exchange Commission voted to approve a rule that Congress included in last year’s Jumpstart Our Business Start-Ups Act, a law meant to help bolster small businesses and create jobs after the financial crisis.”

“The move allows start-ups and small businesses to use advertising to raise money through private offerings. Hedge funds and buyout firms, whose investment vehicles fall under regulations for private offerings, will also be able to promote their products to the general public, though restrictions remain on who can invest in them. Some regulators, lawmakers and consumer protection groups faulted the S.E.C.’s decision. Luis A. Aguilar, the lone dissenter among the S.E.C.’s five commissioners, called the adoption of the rule reckless. He said it was being approved without appropriate investor safeguards and worried that it would lead to abuse.”

SENATORS QUESTION CHINESE TAKEOVER OF SMITHFIELD  |  Members of the Senate Agriculture Committee raised questions on Wednesday about the economic and national security implications of the takeover of Smithfield Foods, the nation’s largest pork producer, by Shuanghui International, a Chinese company. While the chief executive of Smithfield, C. Larry Pope, said the $4.7 billion acquisition would have “no impact on the U.S. food supply and, therefore, no impact on food security,” several senators said they feared that promises by Shuanghui would not be honored over the long term, Edward Wyatt reports in DealBook. That could result, they said, in China eventually exporting pork to the United States that did not meet American safety standards or taking away sales by American companies in other overseas markets, like Japan.

ON THE AGENDA  | 
Texas Industries reports earnings in the morning. Infosys reports earnings after the market closes. Barry Silbert, chief executive of SecondMarket, is on CNBC at 8:10 a.m. Marc Andreessen of Andreessen Horowitz, is on Bloomberg TV at 3 p.m.

A CONSPICUOUS ABSENCE IN SUN VALLEY  |  Many prominent deal makers have descended on the Allen & Company media and technology conference in Sun Valley, Idaho. But one of the most-mentioned individuals is absent: Larry Page, the chief executive of Google. “The search giant is well represented by a number of senior executives, to be sure. Eric Schmidt, the company’s executive chairman, is here. So are Nikesh Arora, its chief business officer, and Salar Kamangar, the chief executive of its YouTube division,” DealBook’s Michael J. de la Merced writes. “But it’s Mr. Page, whom several attendees said they had been hoping to hear speak on Wednesday morning, whose name cropped up an awful lot. The chief executive has disclosed that he suffers from a chronic illness that affects his vocal cords and breathing.”

Still, other chief executives were milling about. Leslie Moonves of CBS said that he was not looking to buy TV stations, but “If they fit, we would” take a look. Jeffrey L. Bewkes, chief of Time Warner, said he thought Aereo, a streaming TV service, is “irrelevant” and that the best buyer of Hulu is Hasbro.

Mergers & Acquisitions »

Sprint Completes Its Deal With SoftBank  |  Sprint said its deal to sell a controlling stake to SoftBank of Japan closed on Wednesday, after a drawn-out bidding process. Sprint is shedding “Nextel” from its corporate name, AllThingsD notes. ALLTHINGSD

Inside Lampert’s Sears  |  Many of the troubles at Sears can be linked to an organizational model that Edward S. Lampert, the chairman, implemented five years ago, Mina Kimes writes in Bloomberg Businessweek. BLOOMBERG BUSINESSWEEK

Noble Group Said to Weigh Bid for Australian Miner  |  The Noble Group is considering a bid for Western Desert Resources, “in what would be one of the biggest deals for an Australian iron-ore miner since prices weakened last year, according to people familiar with the matter,” The Wall Street Journal reports. WALL STREET JOURNAL

Icahn’s Latest Gamble at Dell: Appraisal Rights  |  Carl C. Icahn’s call for shareholders to exercise their appraisal rights is in some ways a surprising shift, since he has pushed them to reject the takeover bid. But it may be a last-ditch effort to seek a higher payout even if the deal goes through. DealBook »

Tribune to Split Newspapers and TV  |  The Tribune Company announced on Wednesday that it would spin off its newspapers and broadcasting properties into separate companies. DealBook »

Why Italy Could Be Fertile Ground for Deal Makers  |  Italy’s shaky state should not be an insurmountable obstacle to foreign investment, Quentin Webb of Reuters Breakingviews writes. Foreign deal makers just need to find ways to coax Italy’s aging entrepreneur-owners to the table. REUTERS BREAKINGVIEWS

INVESTMENT BANKING »

At Deutsche Bank, Loans That Are Less Than Transparent  |  Deutsche Bank “made billions of dollars of loans to banks worldwide since 2008 and accounted for them in a way that obscured their continuing risk to investors,” Bloomberg News reports. BLOOMBERG NEWS

An Improvement in How Banks Are Perceived by Consumers  |  Perceptions of Goldman Sachs, Bank of America, JPMorgan Chase and Morgan Stanley have improved in the first half of year compared with a year earlier, according to the YouGov BrandIndex. YOUGOV

Evercore to Start a Private Capital Advisory Business  |  Evercore Partners, an investment banking advisory firm, said on Wednesday that it was starting a private capital advisory business and had hired two UBS bankers to lead it. DealBook »

Barclays Wins Dismissal of Lawsuit Over Sale of Securities  |  A judge dismissed a lawsuit from the National Credit Union Administration, which regulates credit unions, over the sale of more than $555 million of mortgage-backed securities to two credit unions, Reuters reports. REUTERS

PRIVATE EQUITY »

A Bleak Outlook for Private Equity in India  |  Nikhil Raghavan, a principal at Bain Capital in Mumbai, predicted that private equity investments in India would probably fall this year because of a lack of opportunities, The Wall Street Journal writes. WALL STREET JOURNAL

HEDGE FUNDS »

Hedge Fund Glory Days May Be Over  |  “After a decade as rock stars, hedge fund managers seem to be fading just as quickly as musicians do,” Sheelah Kolhatkar writes in the Bloomberg Businessweek cover story. BLOOMBERG BUSINESSWEEK

Adventures Abroad Could Hurt U.S. Companies  |  It is astounding how little risk the markets are pricing into public companies that have poured shareholder money into emerging markets over the last several years through acquisitions and start-up projects, writes Carson C. Block, the director of research for the investment firm Muddy Waters. DealBook »

LightSquared to Go to Trial With Lenders  | 
REUTERS

I.P.O./OFFERINGS »

Royal Mail Employees to Get Free Shares in I.P.O.Royal Mail Employees to Get Free Shares in I.P.O.  |  The British government’s plans to sell a majority stake in Royal Mail would be the biggest privatization in the country since the railroads 20 years ago. DealBook »

VENTURE CAPITAL »

With a Silicon Valley Fortune, a Hunt for Political Office  |  Sean Eldridge, the husband of the Facebook co-founder Chris Hughes, has relocated in a quest for a congressional seat in New York, The New York Times writes. “But his ambitions have puzzled some residents among the farmers, mill workers and small-business owners who populate this district, which rises through the Catskills and rolls north through cornfields and apple orchards to the Vermont border.” NEW YORK TIMES

LEGAL/REGULATORY »

At Fed, Diverging Debate on When to End Stimulus  |  The New York Times reports: “The Federal Reserve chairman, Ben S. Bernanke, said on Wednesday that the Fed was likely to extend the centerpiece of its campaign to bolster the economy â€" keeping short-term interest rates close to zero â€" even as it prepares to wind down another key stimulus program that faces mounting internal opposition.” NEW YORK TIMES

Fed’s Easing of Stimulus Could Hamper European Recovery  |  “Recent fears that the Federal Reserve could begin withdrawing its economic stimulus have prompted interest rates to rise around the world, putting business loans further out of reach for companies in Spain, Italy and France,” The New York Times writes. NEW YORK TIMES

Massachusetts Regulator Opens Inquiry Into Products Sold to Older Investors  |  The top financial regulator in Massachusetts has asked 15 brokerage firms, including Merrill Lynch and LPL Financial, about the way they have marketed “high-risk, esoteric products” to older investors. DealBook »

The Consequences of Apple’s Loss on E-Books  |  A federal judge on Wednesday ruled that Apple had violated antitrust law in conspiring with publishers to raise prices of e-books. “Although it appears unlikely that the ruling will have an immediate effect on the book-buying public, it could affect how Apple cuts deals with media companies that provide the music, books and movies that help make its iPhones and iPads compelling,” The New York Times reports. NEW YORK TIMES

What Is Bank Capital, Anyway?  |  Though capital is a centerpiece of Wall Street regulation, it resists a simple definition.
DealBook »

China’s Growth Woes Could Force Government Response  |  The Chinese government’s response to weak economic data will be a test of the nation’s new leadership, Bill Bishop writes in the China Insider column. DealBook »